No Data
No Data
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Express News | Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
No Data
No Data